MX2018009867A - Metodos que comprenden una dosificacion intermitente fija de cediranib. - Google Patents

Metodos que comprenden una dosificacion intermitente fija de cediranib.

Info

Publication number
MX2018009867A
MX2018009867A MX2018009867A MX2018009867A MX2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A
Authority
MX
Mexico
Prior art keywords
cediranib
administration
methods
composition
consecutive days
Prior art date
Application number
MX2018009867A
Other languages
English (en)
Inventor
Barry Simon
Kendrew Jane
Ho Tony
Robert Wedge Stephen
Percy Ivy Susan
KOHN Elise
Min LEE Jung-
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018009867A publication Critical patent/MX2018009867A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se divulgan métodos que comprenden ciclos repetidos de administración de una composición que comprende cediranib de acuerdo con un patrón posológico intermitente fijo que comprende la administración de una cantidad eficaz de la composición que comprende cediranib en uno o más días consecutivos de un ciclo seguidos por uno o más días consecutivos de descanso en los cuales no se administra dicha composición, y se pueden utilizar como monoterapia o pueden comprender la administración de una o más terapias o fármacos asociados y se pueden utilizar en la terapia combinada. Tales métodos pueden producir un efecto antiangiogénico y/o reductor de la permeabilidad vascular, tratar al menos un estado patológico asociado con la angiogénesis, reducir la dosis total de cediranib requerida para proporcionar una inhibición de VEGF eficaz, reducir los eventos adversos y toxicidad debidos a la administración de cediranib, mantener la actuación sobre la ruta de VEGF a pesar de la reducción de las dosis totales de cediranib, y/o incrementar la reparación de tejido sano, no canceroso durante el tratamiento de cáncer utilizando terapias combinadas.
MX2018009867A 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib. MX2018009867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (1)

Publication Number Publication Date
MX2018009867A true MX2018009867A (es) 2019-05-27

Family

ID=59625551

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009867A MX2018009867A (es) 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Country Status (16)

Country Link
US (1) US20210322415A1 (es)
EP (2) EP4071174A1 (es)
JP (2) JP6865762B2 (es)
KR (1) KR102830910B1 (es)
CN (1) CN109073650A (es)
AU (1) AU2017221268B2 (es)
CA (1) CA3014674C (es)
DK (1) DK3417294T3 (es)
ES (1) ES2906813T3 (es)
HU (1) HUE058114T2 (es)
MA (1) MA44251A (es)
MX (2) MX2018009867A (es)
PL (1) PL3417294T3 (es)
RU (1) RU2740849C2 (es)
TW (1) TWI827530B (es)
WO (1) WO2017142871A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
EP3624850A1 (en) 2017-05-18 2020-03-25 Tesaro, Inc. Combination therapies for treating cancer
KR20200086664A (ko) 2017-09-30 2020-07-17 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
KR20070073813A (ko) * 2004-09-27 2007-07-10 아스트라제네카 아베 Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
EP2262504A1 (en) * 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
KR20110113648A (ko) * 2009-02-04 2011-10-17 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
NO2504364T3 (es) 2009-11-24 2018-01-06
CN106924741A (zh) * 2011-11-08 2017-07-07 因特利凯有限责任公司 使用多种药剂的治疗方案
EP2850067B1 (en) * 2012-05-18 2017-08-16 Sumitomo Dainippon Pharma Co., Ltd. Carboxylic acid compounds
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
NZ721908A (en) * 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
NO2714752T3 (es) * 2014-05-08 2018-04-21
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Also Published As

Publication number Publication date
CA3014674C (en) 2024-06-18
ES2906813T3 (es) 2022-04-20
EP4071174A1 (en) 2022-10-12
PL3417294T3 (pl) 2022-05-09
WO2017142871A1 (en) 2017-08-24
JP7271594B2 (ja) 2023-05-11
CA3014674A1 (en) 2017-08-24
MX2023007826A (es) 2023-07-07
TWI827530B (zh) 2024-01-01
JP6865762B2 (ja) 2021-04-28
CN109073650A (zh) 2018-12-21
EP3417294B8 (en) 2022-05-04
MA44251A (fr) 2018-12-26
AU2017221268A1 (en) 2018-08-30
JP2019504860A (ja) 2019-02-21
KR102830910B1 (ko) 2025-07-04
AU2017221268B2 (en) 2024-02-15
RU2018131377A (ru) 2020-03-17
EP3417294A4 (en) 2019-08-14
EP3417294B1 (en) 2021-12-01
JP2021105039A (ja) 2021-07-26
TW201906610A (zh) 2019-02-16
WO2017142871A8 (en) 2018-06-14
US20210322415A1 (en) 2021-10-21
RU2740849C2 (ru) 2021-01-21
RU2018131377A3 (es) 2020-06-02
DK3417294T3 (da) 2022-02-21
KR20180125456A (ko) 2018-11-23
EP3417294A1 (en) 2018-12-26
HUE058114T2 (hu) 2022-07-28

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
BR112017011536A2 (pt) terapias de combinação
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
ECSP109969A (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл